Clinical Trial

The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2024 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
It is important to assess the implications of genetic variants of the TGF-β1 gene in patients with HFrEF and the association of this polymorphism with treatment response to SGLT2I. Therefore, by correlating the pharmacogenetics hand in hand with the mechanistic markers involved in the pathogenesis of HF, this can aid in the development of individualized, therapeutic strategies and improve the patient's drug response.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06503601
Lead Sponsor Ain Shams University
Conditions Heart Failure
Enrollment 92 participants
Start Date 2023-07-30
Primary Completion 2025-07-30 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-16